Sleep Disturbance, Irritability, and Response to Lurasidone Treatment in Children and Adolescents with Bipolar Depression

por Singh, Manpreet K., Siu, Cynthia, Tocco, Michael, Pikalov, Andrei, Loebel, Antony
Publicado 2023

PM418. Efficacy of Lurasidone in Patients With Schizophrenia With Prominent Positive Symptoms: A Pooled Analysis of Short-Term Placebo-Controlled Studies

por Potkin, Steven G., Tocco, Michael, Mao, Yongcai, Cucchiaro, Josephine, Loebel, Antony
Publicado 2016

Lurasidone in Children and Adolescents with Bipolar Depression Presenting with Mixed (Subsyndromal Hypomanic) Features: Post Hoc Analysis of a Randomized Placebo-Controlled Trial

por Singh, Manpreet K., Pikalov, Andrei, Siu, Cynthia, Tocco, Michael, Loebel, Antony
Publicado 2020

Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia

por Correll, Christoph U., Tocco, Michael, Hsu, Jay, Goldman, Robert, Pikalov, Andrei
Publicado 2022

Important Error in ‘Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer's Disease and Other Dementias’ by Muayqil a...

por Tariot, Pierre N., Wirth, Yvonne, Graham, Stephen M., Tocco, Michael, Fokkens, Jasmine
Publicado 2014

F52. EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 24-MONTH, OPEN-LABEL EXTENSION STUDY

por Goldman, Robert, Tocco, Michael, Pikalov, Andrei, Cucchiaro, Josephine, Deng, Ling, Loebel, Antony
Publicado 2018

Tolerability, Safety, and Effectiveness of Two Years of Treatment with Lurasidone in Children and Adolescents with Bipolar Depression

por DelBello, Melissa P., Tocco, Michael, Pikalov, Andrei, Deng, Ling, Goldman, Robert
Publicado 2021

PM413. Metabolic Syndrome in Patients With Schizophrenia Receiving Long-Term Treatment With Lurasidone, Quetiapine XR, or Risperidone

por Newcomer, John W., Tocco, Michael, Pikalov, Andrei, Zheng, Hanzhe, Cucchiaro, Josephine, Loebel, Antony
Publicado 2016

T5. LURASIDONE AND RISK FOR METABOLIC SYNDROME IN PATIENTS WITH SCHIZOPHRENIA: A COMPREHENSIVE DATABASE ANALYSIS

por Tocco, Michael, Pikalov, Andrei, Hsu, Jay, Cucchiaro, Josephine, Newcomer, John W, Loebel, Antony
Publicado 2018

S73. EFFECT OF LURASIDONE ON COGNITION IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 2-YEAR OPEN-LABEL EXTENSION STUDY

por Harvey, Philip D, Goldman, Robert, Tocco, Michael, Deng, Ling, Cucchiaro, Josephine, Loebel, Antony
Publicado 2018

F60. INFLAMMATORY MARKERS AND COGNITIVE PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH LURASIDONE

por Pikalov, Andrei, Miller, Brian, Siu, Cynthia, Tocco, Michael, Tsai, Joyce, Harvey, Philip, Loebel, Antony
Publicado 2018

Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies

por Costamagna, Isabella, Calisti, Fabrizio, Cattaneo, Agnese, Hsu, Jay, Tocco, Michael, Pikalov, Andrei, Goldman, Robert
Publicado 2021

Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study

por Mattingly, Greg W., Haddad, Peter M., Tocco, Michael, Xu, Jane, Phillips, Debra, Pikalov, Andrei, Loebel, Antony
Publicado 2020

Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studi...

por Hanania, Nicola A, Yohannes, Abebaw M, Ozol-Godfrey, Ayca, Tocco, Michael, Goodin, Thomas, Sharma, Sanjay, Sanjar, Shahin
Publicado 2021

Hospitalization Risk for Adults with Bipolar I Disorder Treated with Oral Atypical Antipsychotics as Adjunctive Therapy with Mood Stabilizers: A Retrospective Analysis of Medicaid...

por Niu, Xiaoli, Dennen, Syvart, Dembek, Carole, Laubmeier, Kimberly, Liu, Yanmei, Veeranki, Phani, Tocco, Michael, Williams, G. Rhys
Publicado 2021